Loading organizations...
§ Private Profile · Belfast, Belfast, United Kingdom
Biotech startup developing automated genomic diagnostics for early lung cancer detection, focused on medical and clinical markets.
Biomarx is a Belfast, United Kingdom-based biotechnology startup that develops automated genomic diagnostic technologies specifically focused on the early detection of lung cancer. The enterprise focuses on creating innovative screening solutions designed to identify specific cancer markers at earlier, more treatable stages to improve overall patient outcomes. These specialized diagnostic tools are primarily targeted toward medical and clinical markets, including hospitals, specialized oncology clinics, and broader healthcare systems such as the United Kingdom National Health Service. Operating within the broader healthcare and oncology sectors, the business functions on a business-to-business model to provide medical professionals with advanced testing capabilities. To support its ongoing research and commercialization efforts, the organization has successfully secured £700,000 in pre-seed funding to advance its proprietary genomic testing platforms. Biomarx was founded by Sean Macfarlane to address critical gaps in current respiratory oncology screening protocols.
Biomarx has raised $940K across 1 funding round.
Biomarx has raised $940K in total across 1 funding round.
Biomarx has raised $940K across 1 funding round. Most recently, it raised $940K Pre-Seed in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 5, 2026 | $940K Pre Seed | Clarendon Fund Managers, SFC Capital | Techstart Ventures, Catherine Breslin, Intertradeireland | Announced |
Biomarx has raised $940K in total across 1 funding round.
Biomarx's investors include Clarendon Fund Managers, SFC Capital, Techstart Ventures, Catherine Breslin, InterTradeIreland.